Advancing Oncology Research and Minimal Residual Disease Detection with Inocras’s Whole Genome Cancer Platform
Thursday, May 22, 2025
Tweet
Transcript
Embed
Email
Bookmark
<<
<
>
>>
Tweet
Facebook
Email
Chapters
Introduction
Our speakers and agenda
Introducing Inocras
Applying whole genome to cancer profiling Dx and MRD test
What do you see with whole genome?
CancerVision™. Curating vast WG data to actionable insights
CancerVision: Head-to-head comparison with TSO500; TE-WGS presents additional insights not captured in standard panel sequencing
CancerVision: More accurate genome-wide markers, reducing false positive significantly
CancerVision vs. Panel: Evaluating the Added Clinical Value of WGS in Prostate Cancer
CancerVision Detected 96% of Clinically Reported Variants—With Added Insights
Uncovering Clinically Actionable with CancerVision
MRDVisionTM: Whole genome x whole genome approach
MRDVision: Analytical validation methodology and results
MRDVision Clinical validation - as low as 1 ppm sensitivity
MRDVision Clinical validation - Orthogonal study results
MRDVision Clinical validation - Orthogonal study results
MRDVision delivers accuracy, affordability, and more WGS data
Panel Discussion
No transcript for this webinar
More Information
Request info